Benitec Biopharma Restates Financials, Cites Material Weakness

TL;DR

**Benitec's restatement and control weakness are a red flag; proceed with extreme caution until remediation is proven effective.**

AI Summary

Benitec Biopharma Inc. (BNTC) filed its 10-K for the fiscal year ended June 30, 2025, revealing a restatement of prior period financial statements due to unrecorded non-cash share-based compensation expenses. This error, stemming from an incorrectly configured equity awards data system migrated in November 2023, led to understatements of additional paid-in capital, accumulated deficit, net loss, and loss per share for the quarters ended December 31, 2024, and March 31, 2025. The company's Audit Committee, in consultation with management and Baker Tilly US, LLP, concluded these prior financial statements should no longer be relied upon. As a result of the restatement, management identified a material weakness in the company's internal control over financial reporting as of June 30, 2025, and is actively working on remediation. BNTC, a clinical-stage biotechnology company, is focused on advancing its proprietary DNA-directed RNA interference (ddRNAi) and 'silence and replace' platforms, with its lead candidate BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD) having Orphan Drug Designation in the U.S. and E.U. The aggregate market value of common equity held by non-affiliates was approximately $152,964,292 as of December 31, 2024, based on a closing price of $12.63.

Why It Matters

This restatement and identified material weakness in internal controls are critical for investors, signaling potential instability in financial reporting and raising questions about management oversight. For employees and customers, while the core business of developing genetic medicines like BB-301 continues, financial missteps can impact confidence and future funding. In the competitive biotechnology market, where investor trust is paramount for funding R&D, such disclosures can deter new investment and put BNTC at a disadvantage against rivals with cleaner financial records. The need for additional financing to progress product candidates, as stated in the filing, becomes more challenging with these issues.

Risk Assessment

Risk Level: high — The filing explicitly states a 'material weakness exists in the Company's internal control over financial reporting as of June 30, 2025' due to incorrectly recorded non-cash share-based compensation expenses. This led to a restatement of financial statements for the quarters ended December 31, 2024, and March 31, 2025, indicating significant deficiencies in financial reporting processes. The company also noted the cumulative impact of the incorrect configuration had a 'material effect' on prior unaudited consolidated financial statements.

Analyst Insight

Investors should exercise extreme caution and consider delaying any investment decisions until Benitec Biopharma Inc. demonstrates successful remediation of its material weakness in internal controls. Monitor subsequent filings for updates on the remediation plan and its effectiveness, as continued financial reporting issues could severely impact investor confidence and stock performance.

Key Numbers

• $152,964,292 — Aggregate market value of common equity held by non-affiliates (as of December 31, 2024, based on a closing price of $12.63)
• 26,250,469 — Shares of common stock outstanding (on September 17, 2025)
• $12.63 — Closing price of common stock (on December 31, 2024)
• June 30, 2025 — Fiscal year end (date for which the 10-K was filed and material weakness identified)
• November 2023 — Date of equity awards data migration (when the incorrect system configuration occurred)
• 1-for-17 — Reverse stock split ratio (effective July 26, 2023)

Key Players & Entities

• Benitec Biopharma Inc. (company) — registrant of the 10-K filing
• Baker Tilly US, LLP (company) — independent registered public accounting firm consulted by the Audit Committee
• Audit Committee (company) — concluded prior financial statements should not be relied upon
• BB-301 (company) — lead therapeutic candidate for OPMD
• Oculopharyngeal Muscular Dystrophy (company) — disease targeted by BB-301
• Nasdaq Stock Market LLC (regulator) — exchange where BNTC common stock is registered
• U.S. Securities and Exchange Commission (regulator) — regulatory body for 10-K filing
• Delaware (company) — state of incorporation for Benitec Biopharma Inc.
• Hayward, California (company) — headquarters location for Benitec Biopharma Inc.
• Benitec Limited (company) — subsidiary of Benitec Biopharma Inc.

FAQ

Risk Factors

• Material Weakness in Internal Control Over Financial Reporting [high — operational]: The company identified a material weakness in its internal control over financial reporting as of June 30, 2025, due to an incorrectly configured equity awards data system. This led to a restatement of prior period financial statements, impacting additional paid-in capital, accumulated deficit, net loss, and loss per share. Remediation efforts are underway.
• Restatement of Financial Statements [high — financial]: Benitec Biopharma restated its financial statements for prior periods due to unrecorded non-cash share-based compensation expenses. This restatement indicates potential inaccuracies in previous financial reporting and a lack of reliable financial information for those periods.
• Dependence on Orphan Drug Designation [medium — regulatory]: The company's lead candidate, BB-301, has Orphan Drug Designation in the U.S. and E.U. While this offers market exclusivity and other benefits, the success of the company is heavily reliant on the successful development and commercialization of this single candidate.
• Clinical Trial and Development Risks [high — market]: As a clinical-stage biotechnology company, Benitec Biopharma faces significant risks associated with the lengthy, expensive, and uncertain process of clinical trials and drug development. Failure to demonstrate safety and efficacy in trials can lead to significant financial losses and project abandonment.
• Need for Future Financing [high — financial]: The company's operations are capital-intensive, and it will likely require substantial additional funding to support ongoing research and development, clinical trials, and potential commercialization. There is no assurance that such financing will be available on acceptable terms.
• Competition in Biotechnology Sector [medium — market]: The biotechnology industry is highly competitive, with numerous companies developing therapies for similar diseases. Benitec Biopharma faces competition from established pharmaceutical companies and other emerging biotechs, which could impact market share and pricing.
• Reliance on Key Personnel [medium — operational]: The success of Benitec Biopharma is dependent on its ability to attract and retain highly qualified scientific and management personnel. The loss of key individuals could adversely affect its ability to execute its business strategy.
• Intellectual Property Risks [medium — legal]: The company's ability to protect its intellectual property, including patents related to its ddRNAi technology, is critical. Challenges to its patents or failure to secure adequate patent protection could harm its competitive position.

Industry Context

Benitec Biopharma operates in the highly competitive and rapidly evolving biotechnology sector, focusing on gene silencing therapies. The industry is characterized by significant R&D investment, long development cycles, and high regulatory hurdles. Companies like Benitec compete with both established pharmaceutical giants and numerous emerging biotechs, all vying for breakthroughs in treating rare and complex diseases.

Regulatory Implications

The company's reliance on Orphan Drug Designation for its lead candidate, BB-301, highlights the importance of regulatory pathways for rare disease treatments. However, the identification of a material weakness in internal controls poses a significant regulatory risk, potentially leading to increased scrutiny from the SEC and investors regarding financial reporting accuracy and compliance.

What Investors Should Do

1. Monitor remediation of material weakness
2. Evaluate clinical trial progress for BB-301
3. Assess future financing needs and dilution risk
4. Review the impact of the financial restatement

Key Dates

• 2025-06-30: Fiscal Year End — Date as of which the 10-K was filed and a material weakness in internal control over financial reporting was identified.
• 2024-12-31: Aggregate Market Value of Common Equity Held by Non-Affiliates — Reported at $152,964,292 based on a closing price of $12.63, indicating a significant market capitalization at that time.
• 2024-12-31: Prior Period Financial Statements Restated — Financial statements for quarters ending December 31, 2024, and March 31, 2025, were identified as unreliable due to unrecorded compensation expenses.
• 2023-11-01: Equity Awards Data System Migration — The migration of the equity awards data system in November 2023 led to incorrect configuration and subsequent unrecorded expenses, causing the financial restatement.
• 2023-07-26: Reverse Stock Split — A 1-for-17 reverse stock split was effective on this date, which impacts the number of shares outstanding and per-share metrics.

Glossary

DNA-directed RNA interference (ddRNAi)

A proprietary technology platform developed by Benitec Biopharma that uses RNA interference to silence specific genes, potentially treating genetic diseases. (This is the core technology platform for Benitec Biopharma's drug development pipeline.)

Oculopharyngeal Muscular Dystrophy (OPMD)

A rare, late-onset genetic disorder that affects muscles in the eyelids and throat, leading to ptosis and dysphagia. (Benitec Biopharma's lead candidate, BB-301, is being developed to treat OPMD.)

Orphan Drug Designation

A status granted by regulatory authorities (like the FDA or EMA) to drugs intended to treat rare diseases, offering incentives such as market exclusivity and tax credits. (BB-301 has Orphan Drug Designation, which is a positive step for its development and potential commercialization.)

Material Weakness

A deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis. (The identification of a material weakness indicates significant issues with the company's financial reporting controls, leading to the restatement.)

Restatement

The process of correcting previously issued financial statements that were found to be materially misstated. (Benitec Biopharma has restated its financial statements due to errors in accounting for share-based compensation.)

Additional Paid-In Capital

An equity account that represents the amount of money investors have paid for stock above its par value. (The restatement due to unrecorded compensation expenses impacted this account, showing an understatement.)

Accumulated Deficit

The cumulative net losses of a company since its inception, less any cumulative net income. (The restatement resulted in an understatement of the accumulated deficit.)

Non-cash share-based compensation expenses

Expenses recognized for employee stock options, restricted stock units, or other equity awards that do not involve an outflow of cash. (These unrecorded expenses were the direct cause of the financial restatement.)

Year-Over-Year Comparison

Information comparing key metrics to the previous year's filing is not available in the provided text. However, the current filing highlights a significant issue with a restatement of prior period financial statements due to unrecorded non-cash share-based compensation expenses. This indicates a material weakness in internal controls over financial reporting as of June 30, 2025, which was not a disclosed issue in prior filings.

Key Financial Figures

• $0.0001 B — ich registered Common Stock, par value $0.0001 BNTC The Nasdaq Stock Market LLC Secu
• $12.63 — urities on the Nasdaq Capital Market of $12.63 on December 31, 2024 was approximately
• $0.0001 — hares of the Registrant's common stock, $0.0001 par value per share, outstanding on Sep

Filing Documents

• d57150d10k.htm (10-K) — 2432KB
• d57150dex211.htm (EX-21.1) — 3KB
• d57150dex231.htm (EX-23.1) — 3KB
• d57150dex311.htm (EX-31.1) — 11KB
• d57150dex312.htm (EX-31.2) — 11KB
• d57150dex321.htm (EX-32.1) — 4KB
• d57150dex322.htm (EX-32.2) — 4KB
• d57150dex97.htm (EX-97) — 35KB
• g57150g09k54.jpg (GRAPHIC) — 120KB
• g57150g09k56.jpg (GRAPHIC) — 113KB
• g57150g09k59.jpg (GRAPHIC) — 118KB
• g57150g12j10.jpg (GRAPHIC) — 201KB
• g57150g67p99.jpg (GRAPHIC) — 233KB
• 0001193125-25-211361.txt ( ) — 13771KB
• bntc-20250630.xsd (EX-101.SCH) — 1433KB
• d57150d10k_htm.xml (XML) — 2533KB

, Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations

Part II, Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations

, Item 8, Financial Statements and Supplementary Data

Part II, Item 8, Financial Statements and Supplementary Data

, Item 15, Exhibits and Financial Statement Schedules

Part IV, Item 15, Exhibits and Financial Statement Schedules Table of Contents BENITEC BIOPHARMA INC. ANNUAL REPORT ON FORM 10-K TABLE OF CONTENTS Page PART I Item 1.

Business

Business 3 Item 1A.

Risk Factors

Risk Factors 28 Item 1B. Unresolved Staff Comments 70 Item 1C. Cybersecurity 70 Item 2.

Properties

Properties 70 Item 3.

Legal Proceedings

Legal Proceedings 70 Item 4. Mine Safety Disclosures 70 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 71 Item 6. RESERVED 71 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 72 Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 80 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data F-1 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 81 Item 9A.

Controls and Procedures

Controls and Procedures 81 Item 9B. Other Information 83 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. 83 PART III Item 10. Directors, Executive Officers and Corporate Governance III-1 Item 11.

Executive Compensation

Executive Compensation III-1 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters III-1 Item 13. Certain Relationships and Related Transactions, and Director Independence III-1 Item 14. Principal Accountant Fees and Services III-1 PART IV Item 15. Exhibits and Financial Statement Schedules IV-1 Item 16. Form 10-K Summary IV-4

Signatures

Signatures IV-5 Table of Contents PART I ABOUT THIS ANNUAL REPORT Unless the context otherwise requires, the terms "Benitec," the "Company," "we," "us," "our" and similar terms used in this Annual Report on Form 10-K refer to Benitec Biopharma Inc., a Delaware corporation, and its subsidiaries (including Benitec Limited). Any references to "Benitec Limited" or "BBL" refer to Benitec Biopharma Limited, an Australian corporation. All references to "$" in this Annual Report refer to U.S. dollars. Any references to "A$" in this Annual Report mean Australian dollars. As of June 30, 2025, the rate of exchange of U.S. dollars to Australian dollars was 1.5265 AUD. Our fiscal year-end is June 30. References to a particular "fiscal year" are to our fiscal year ended June 30 of that calendar year. Except as otherwise stated, all share and earnings per share amounts presented in this Annual Report reflect the impact of the 1-for-17 reverse stock split of the Company's common stock effective July 26, 2023. INDUSTRY AND MARKET DATA This Annual Report includes information with respect to market and industry conditions and market share from third-party sources or based upon estimates using such sources when available. We believe that such information and estimates are reasonable and reliable. We also believe the information extracted from publications of third- party sources has been accurately reproduced. However, we have not independently verified any of the data from third-party sources. Similarly, our internal research is based upon our understanding of industry conditions, and such information has not been verified by any independent sources. TRADEMARKS AND TRADENAMES We have proprietary and licensed rights to trademarks used in this Annual Report which are important to our business, many of which are registered under applicable intellectual property laws. Our trademarks include: BENITEC BIOPHARMA BENITEC GIVING DISEASE THE SILENT TREATMENT SILE

View Full Filing

View this 10-K filing on SEC EDGAR